Skip to content
Homepage
Author:
Hangzhou Deshi Biotechnology Co., Ltd
Posted Date:
April 30, 2026
Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine
Hangzhou Deshi Biotechnology Co., Ltd
April 30, 2026
Diagens Biotechnology Raises US$101 Million in Hong Kong IPO; Shares More Than Double on First Day of Trading
Hangzhou Deshi Biotechnology Co., Ltd
March 31, 2026
